Endoscopic response to subcutaneous infliximab by disease location: A post hoc analysis of the LIBERTY-CD study

Inflammatory Bowel Disease

Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE Trial

Inflamm Bowel Dis

Ahuja D, Anvari S, Wong ECL, Dulai P, Marshall JK, Jairath V, Reinisch W, Narula N

doi: 10.1093/ibd/izaf137

Inflammatory Bowel Disease

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study

Inflamm Bowel Dis

Boute EH, Gianolio L, Mahmmod S, Pochesci S, Armstrong K, Henderson P, Wilson DC, de Ridder L, Russell RK, Escher JC

doi: 10.1093/ibd/izaf335

Inflammatory Bowel Disease

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

J Crohns Colitis

Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB

doi: 10.1093/ecco-jcc/jjaf060

Inflammatory Bowel Disease

Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn's Disease: A Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol

Lee HH, Yuan Y, Boland BS, Chang JT, Jairath V, Singh S

doi: 10.1016/j.cgh.2025.07.009

Inflammatory Bowel Disease

Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic Disease

Am J Gastroenterol

Wong ECL, Jairath V, Dulai PS, Marshall JK, Ma C, Reinisch W, Narula N

doi: 10.14309/ajg.0000000000003940

Inflammatory Bowel Disease

Immunogenicity and efficacy of subcutaneous infliximab monotherapy versus combination therapy in IBD: a systematic review and meta-analysis

Clin Gastroenterol Hepatol

Anjie SI, Gecse KB, Meloni CM, Vidal-Itriago A, Löwenberg M, D'Haens GR

doi: 10.1016/j.cgh.2025.03.021

Inflammatory Bowel Disease

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Gastroenterology

Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G

doi: 10.1053/j.gastro.2025.02.033

Inflammatory Bowel Disease

Prognostic Significance of Different Endoscopic Scores in Post-Operative Crohn's Disease and their Role in Patients with Low-Risk Features

Adv Ther

Del Gaudio A, Parisio L, Privitera G, Cuccia G, Coppola G, Laterza L, Lopetuso LR, Gasbarrini A, Carbone L, Papa A, Scaldaferri F, Pugliese D

doi: 10.1007/s12325-025-03466-3

Inflammatory Bowel Disease

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

Lancet Gastroenterol Hepatol

D'Haens GR, Löwenberg M, Baert F, Bossuyt P, Molnár T, Hoentjen F, Clasquin E, Gecse KB, Hulshoff MS, De Hertogh G, Lenfant M, Oldenburg L, Vermeire S

doi: 10.1016/S2468-1253(25)00233-X

Related content

Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE Trial

Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn's Disease: A Systematic Review and Meta-analysis

Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic Disease

Immunogenicity and efficacy of subcutaneous infliximab monotherapy versus combination therapy in IBD: a systematic review and meta-analysis

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Prognostic Significance of Different Endoscopic Scores in Post-Operative Crohn's Disease and their Role in Patients with Low-Risk Features

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study